SODIUM ZIRCONIUM CYCLOSILICATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SODIUM ZIRCONIUM CYCLOSILICATE (SODIUM ZIRCONIUM CYCLOSILICATE).
Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.
| Metabolism | Sodium zirconium cyclosilicate is not systemically absorbed and is eliminated unchanged in feces. No hepatic metabolism or cytochrome P450 involvement. |
| Excretion | Primarily eliminated unchanged in feces (>99%); negligible renal excretion (<1%) as the drug is not absorbed systemically. |
| Half-life | Not applicable as the drug acts locally in the GI tract without systemic absorption; clinical effect persists for duration of dosing. |
| Protein binding | Not applicable; <0.1% absorbed systemically, so protein binding is negligible. |
| Volume of Distribution | Not applicable; negligible systemic distribution due to lack of absorption (Vd not measurable). |
| Bioavailability | Oral: <0.1% due to minimal absorption; acts locally in gastrointestinal tract. |
| Onset of Action | Oral: reduction in serum potassium begins within 1 hour; maximal effect may take 24–48 hours. |
| Duration of Action | Duration of action is dependent on dosing interval; sustained effect with repeated administration; potassium lowering persists for at least 24 hours after each dose. |
5 g orally three times daily.
| Dosage form | POWDER, FOR SUSPENSION |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to potential for electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SODIUM ZIRCONIUM CYCLOSILICATE (SODIUM ZIRCONIUM CYCLOSILICATE).
| Breastfeeding | No data on excretion in human milk. Sodium zirconium cyclosilicate is non-systemic and minimally absorbed (<1% oral dose), unlikely to enter breast milk. M/P ratio not calculated due to negligible systemic absorption. |
| Teratogenic Risk | Limited human data; animal studies show no teratogenic effects at clinically relevant exposures. Not associated with structural abnormalities in first trimester. Theoretical risk of electrolyte disturbances affecting fetal development if maternal electrolyte imbalance occurs. No known risk in second or third trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Absolute: Hypersensitivity to sodium zirconium cyclosilicate or any component.","Relative: Severe constipation, bowel obstruction, or impaired GI motility (e.g., postoperative ileus) – use only if benefits outweigh risks.","Relative: Concomitant use with agents that cause constipation or reduce GI motility."]
| Precautions | ["Edema: Contains sodium; caution in patients with heart failure or requiring sodium restriction (each 5 g dose provides ~400 mg sodium).","Gastrointestinal effects: Constipation, fecal impaction (especially in elderly or those with decreased GI motility).","Hypokalemia: Monitor serum potassium regularly; may cause hypokalemia if not titrated appropriately.","Drug interactions: Separate dosing from oral medications (take at least 2 hours apart) due to potential adsorption.","Severe constipation: Discontinue if bowel obstruction suspected."] |
Loading safety data…
| Fetal Monitoring | Serum potassium levels before and during therapy; monitor for hypokalemia. Serum magnesium, sodium, and bicarbonate periodically. Fetal monitoring only if maternal electrolyte disturbances occur; no specific fetal monitoring required. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment of male or female fertility at doses up to 10 times the maximum recommended human dose (based on body surface area). |